Iteos Therapeutics — JPM HC Conference January 2025
29 slides from Iteos Therapeutics's conference presentation, Jan 13, 2025

Slide 1: Advancing Science. Designing Hope.
Advancing Science. Designing Hope. JPM HC Conference January 2025

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possib

Slide 3: 2025: Pivotal Year of Datasets
2025: Pivotal Year of Datasets 01 03 >400 PATIENTS IN 2025 FUNDED THROUGH OF TIGIT:PD-1 DATA IMPACTFUL MILESTONES GALAXIES Lung-201 ~$684M* in Cash, Runway Through 2027 GALAXIES H&N-202 TIG-006 H&N 02 EMERGING PIPELINE OF FIRST-IN-CLASS OPPORTUNITIES EOS-984: Restoring T Cell Proliferation EOS-215:

Slide 4: Multiple Clinical Data Readouts in 2025
Multiple Clinical Data Readouts in 2025 Innovative molecules and compelling combinations Preclinical Phase 1 Phase 2 Phase 3 Status Belrestotug: IgG1 antibody targeting TIGIT GALAXIES Lung-301 + dostarlimab | 1L NSCLC PD-LI high GALAXIES Lung-301 Enrolling + dostarlimab | + CD96 | 1L NSCLC PD-L1high

Slide 5: Belrestotug
Belrestotug EOS-448 / GSK4428859A iTeos and GSK are uniquely positioned to leverage the TIGIT/CD226 axis 5

Slide 6: Advancing a Leading TIGIT:PD-1 in an Evolving Landscape
Advancing a Leading TIGIT:PD-1 in an Evolving Landscape GALAXIES Quality of Indication Optimizing Lung-201 Components Selection Trial Design Matters Importance 6

Slide 7: The Need for a Transformative TIGIT:PD-1 Doublet
The Need for a Transformative TIGIT:PD-1 Doublet Belrestotug + dostarlimab represent potentially differentiated, high-quality therapies Monotherapy SKY-01 Fc Silent Activity1 TIGIT All Phase 2s Negative4 GAL-201 ESMO Discontinuation3 Stopped6 Trials Stopped5 ARC-107 Data2 Dostarlimab Market Leading

Slide 8: Belrestotug: The First And Only TIGIT to Demonstrate Robust Target Engagement
Belrestotug: The First And Only TIGIT to Demonstrate Robust Target Engagement TIGIT+ Treg Depletion in Patients Unique Epitope Binding 100% High Affinity + Potency 80% First and only TIGIT with proven Treg depletion at all doses 20-30%2 1 Mild Treg depletion3 Undisclosed* Fc Silent* 0% Only TIGIT to

Slide 9: Belrestotug + Dostarlimab: Strong Efficacy and Clear Differentiation
Belrestotug + Dostarlimab: Strong Efficacy and Clear Differentiation Best Observed Response 100 (Without Confirmation): 90 Dostarlimab (N=32) PR ~60% ORR, 30% ORR Separation 80 70 SD change from baseline1 Maximum percentage 60 50 PD 40 observed at every dose vs dostarlimab monotherapy 30 PD 20 SD SD

Slide 10: GALAXIES Lung-201 - Phase 2 in 1L NSCLC
GALAXIES Lung-201 - Phase 2 in 1L NSCLC Largest TIGIT Phase 2 in PD-L1 high 1L NSCLC n=60 Pembrolizumab 200mg LUNG-201 n=100 Dostarlimab 500mg Key R Subjects Randomization n=30 Dostarlimab 500mg + Belrestotug 100mg R n=60 Dostarlimab 500mg + Belrestotug 400mg n=30 Dostarlimab 500mg + Belrestotug 100

Slide 11: Clinically Meaningful ORR Observed at Every Dose vs Dostarlimab Monotherapy
Clinically Meaningful ORR Observed at Every Dose vs Dostarlimab Monotherapy A: Belrestotug 100 mg + B: Belrestotug 400 mg + C: Belrestotug 1000 mg + Dostarlimab Response measure in mITT dostarlimab dostarlimab dostarlimab N=32 N=30 N=32 N=30 Median follow-up, months (range)1 7.0 (0.2–16.6) 8.5 (0.3–

Slide 12: Consistently Increased Depth of Response vs Dostarlimab Monotherapy
Belrestotug + Dostarlimab Consistently Increased Depth of Response vs Dostarlimab Monotherapy 100 100 90 80 Dostarlimab (N=32) 90 80 A: Belrestotug 100 mg + dostarlimab (N=30) change from baseline1 change from baseline1 70 70 Maximum percentage Maximum percentage 60 60 50 50 40 40 30 PD 30 PD 20 20

Slide 13: Consistent Deep Tumor Reduction with Ongoing Responses
Consistent Deep Tumor Reduction with Ongoing Responses by Belrestotug + Dostarlimab vs Dostarlimab Monotherapy 80 80 Dostarlimab (N=32) A: Belrestotug 100 mg + dostarlimab (N=30) 60 60 40 40 Percentage change Percentage change from baseline1 from baseline1 20 20 0 0 -20 -20 -40 -40 -60 -60 -80 -80 O

Slide 14: Numerically Greater Reduction of ctDNA with Belrestotug Cohorts
Numerically Greater Reduction of ctDNA Associated with Belrestotug 400mg and 1000mg + Dostarlimab Cohorts Best Observed Response 1000 Kruskal-Wallis, p=0.073 (Without Confirmation): 700 PR 500 SD 300 PD 200 100 ctDNA % change at Week 71 0 Molecular -50 response threshold2 -80 -90 -95 -98 -100 Dostar

Slide 15: Belrestotug + Dostarlimab Is Broadly Consistent with Known Safety Profile
Belrestotug + Dostarlimab Is Broadly Consistent with Known Safety Profile of Checkpoint Inhibitor Combinations Increase in immune-related adverse events with belrestotug + dostarlimab vs dostarlimab Dostarlimab A: Belrestotug 100 mg + B: Belrestotug 400 mg + C: Belrestotug 1000 mg Event, n (%) (N=32

Slide 16: Belrestotug + Dostarlimab Is Broadly Consistent with Known Safety Profile
Belrestotug + Dostarlimab Is Broadly Consistent with Known Safety Profile of Checkpoint Inhibitor Combinations Most common TR-irAE were skin and subcutaneous tissue disorders Dostarlimab A: Belrestotug 100 mg + B: Belrestotug 400 mg + C: Belrestotug 1000 mg Event, n (%) N=32 dostarlimab (N=30) dosta

Slide 17: GALAXIES Lung-301 - Phase 3 in 1L NSCLC
GALAXIES Lung-301 - Phase 3 in 1L NSCLC LUNG-301 Key Dostarlimab 500mg + Belrestotug 400mg R Subjects Randomization R Pembrolizumab + Placebo Study Design Estimated Enrollment 1,000 Status Enrolling Objectives Evaluate belrestotug + dostarlimab safety, efficacy vs placebo + pembrolizumab Masking Dou

Slide 18: GALAXIES H&N-202 - Phase 2 in 1L HNSCC
GALAXIES H&N-202 - Phase 2 in 1L HNSCC n=72 Dostarlimab H&N-202 n=72 Dostarlimab + Belrestotug Key R Subjects Randomization R n=72 Dostarlimab + Nelistotug (CD96) n=72 Dostarlimab + Belrestotug + Nelistotug (CD96) n=72 Dostarlimab + PVRIG (GSK4381562) Study Design Estimated Enrollment 360 Status Enr

Slide 19: TIG-006 – Phase 2 in 1L HNSCC PDL1 High/Low
TIG-006 – Phase 2 in 1L HNSCC PDL1High/Low Key R Subjects Randomization Dostarlimab + CPS High ≥ 20 Belrestotug (Dose B) R Dostarlimab + CPS Low < 20 Belrestotug (Dose B) Study Design Estimated Enrollment 40 Status Enrolling Objectives Evaluate belrestotug + dostarlimab in two CPS populations Maskin

Slide 20: On Track for Robust TIGIT Datasets in 2025
On Track for 3 Robust TIGIT Datasets in 2025 Data readouts with >400 patients from TIGIT:PD-1 trials in 1L NSCLC and 1L HNSCC Topline Data in 2Q25 Interim Data in 2025 GALAXIES Lung-201 GALAXIES H&N-202 TIG-006 HNSCC ESMO 2024 New Patients 2025 2025 Dostarlimab 32 30 40 - Belrestotug 100mg + Dostarl

Slide 21: EOS-984
EOS-984 Potential first-in-class small molecule targeting ENT1 21

Slide 22: Intracellular Adenosine: the Key Driver of Immunosuppression
Intracellular Adenosine: the Key Driver of Immunosuppression ENT1 plays a central role in adenosine regulation beyond conventional targets • The Pro-Tumoral • Pro-Tumoral The Role Role of Adenosine of Equilibrative A2A Receptor Nucleoside (A2AR) Transporter 1 (ENT1) 1 Cell death and inflammation TME

Slide 23: EOS-984: Enhancing T Cell Proliferation in the Hostile TME
EOS-984: Enhancing T Cell Proliferation in the Hostile TME Potential cornerstone to revive T cell activating therapies Mechanism of Equilibrative Nucleoside Transporter 1 (ENT1) Inhibitor EOS-984 1 Cell death and inflammation The Role of ENT1 High levels of extracellular adenosine • Dominant transpo

Slide 24: Anti-PD-1 Activity Enhanced by Restoration of T Cell Proliferation by EOS-984
Anti-PD-1 Activity Enhanced by Restoration of T Cell Proliferation by EOS-984 EOS-984 + aPD-1 combination maximizes Humanized TNBC model (MDA-MB-231) tumor killing by functional memory T cells containing high adenosine 40 aPD-1 enhances tumor killing 1000 Vehicle 30 Anti-PD-1 % Specific killing acti

Slide 25: EOS-984: Phase 1 in Advanced Solid Tumors
EOS-984: Phase 1 in Advanced Solid Tumors Evaluation of target engagement and impact on T cells in TME EOS-984 (30mg) EOS-984 (Dose C)+ EOS-984 (22.5mg) Pembrolizumab (200mg) EOS-984 (Dose B) + EOS-984 (15mg) Pembrolizumab (200mg) RP2D EOS-984 (10mg) EOS-984 (Dose A) + Pembrolizumab (200mg) EOS-984

Slide 26: EOS-215
EOS-215 Potential best-in-class anti-TREM2 antagonist 26

Slide 27: EOS-215: Reprogramming the Hostile TME
EOS-215: Reprogramming the Hostile TME Targeting TREM2 addresses an overlooked immune axis, overcoming PD-1 resistance Mechanism of Anti-Triggering Receptor Expressed on Myeloid Cells 2 The Role of TREM2 (TREM2) Antagonist EOS-215 • TREM2 regulates myeloid cells to maintain tissue homeostasis by 1 I

Slide 28: 2025: Pivotal Year of Data Generation
2025: Pivotal Year of Data Generation Innovative portfolio leveraging deep tumor immunology expertise Funded Through TIGIT Emerging Pipeline Significant Milestones 1L NSCLC ENT1 ~$684M As of Sept. 30, 2024 Phase 2 GALAXIES Lung-201 interim data Phase 1 APT-008 topline monotherapy + Continued global

Slide 29: Thank You
.iTEOS Thank You THERAPEUTICS
Source: SEC EDGAR · 8-K filed Jan 13, 2025
More decks from Iteos Therapeutics Inc
ESMO 202420 slides · Sep 16, 2024
Investor Presentation (January 2024)27 slides · Jan 10, 2024
Investor Presentation (January 2023)18 slides · Jan 9, 2023
Investor Presentation (January 2022)12 slides · Jan 11, 2022
Corporate Update (April 2021)19 slides · Apr 12, 2021
Investor Presentation (January 2021)16 slides · Jan 11, 2021